Product Information
BREO ELLIPTA 100-25 MCG INHALR is a brand product labeled by GlaxoSmithKline LLC, priced at $6.5027 per EA under NDC 00173085910. Its NADAC has been published 662 times since Dec 18, 2013.
FDA first approved this application on May 10, 2013.
Strength
100; 25 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173085910
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
FLUTICASONE FUROATE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA204275FDA Approved
5/10/2013
On Market Since
8/26/2013
Pharmacological Classes
Price Statistics
The NADAC for BREO ELLIPTA 100-25 MCG INHALR has been published 662 times since Dec 18, 2013, and over the history we have for it it has risen 54.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.5027 per EA |
|---|---|
| All-time high | $6.5151 (Aug 14, 2024) |
| All-time low | $4.1970 (Dec 18, 2013) |
| 52-week high | $6.5080 |
| 52-week low | $6.5027 |
| Median price | $5.7858 |
| Average price | $5.6207 |
| Largest weekly change | +8.0% (Jan 11, 2017) |
| Weeks tracked | 662 |
| Tracking since | Dec 18, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 18% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BREO ELLIPTA 100-25 MCG INHALR?
The current National Average Drug Acquisition Cost (NADAC) for BREO ELLIPTA 100-25 MCG INHALR, manufactured by GlaxoSmithKline LLC, is $6.5027 per EA (NDC 00173085910), effective Aug 19, 2026.
How has the price of BREO ELLIPTA 100-25 MCG INHALR changed over time?
Over the history we have for it, the NADAC for BREO ELLIPTA 100-25 MCG INHALR has risen 54.9%. It has been tracked across 662 weekly CMS publications since Dec 18, 2013.
What are the highest and lowest recorded NADAC prices for BREO ELLIPTA 100-25 MCG INHALR?
Since Dec 18, 2013, the NADAC for BREO ELLIPTA 100-25 MCG INHALR has ranged from a low of $4.1970 (Dec 18, 2013) to a high of $6.5151 (Aug 14, 2024), with a median of $5.7858 per EA.
Are there cheaper alternatives to BREO ELLIPTA 100-25 MCG INHALR?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BREO ELLIPTA 100-25 MCG INHALR, is $5.3594 per EA — about 18% below BREO ELLIPTA 100-25 MCG INHALR.
Who manufactures BREO ELLIPTA 100-25 MCG INHALR?
BREO ELLIPTA 100-25 MCG INHALR (NDC 00173085910) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.